UC-MSC Infusion for HBV-Related Acute-on-Chronic Liver Failure
Status:
Unknown status
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
Hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF) is a severe disease
with high mortality. Our previous study have demonstrated that peripheral infusion of bone
marrow-derived mesenchymal stromal cells (MSCs) weekly for 4 times is safe and improves 24
weeks survival rate of ACLF patients. In this study, we intend to assess the safety and
efficacy of umbilical cord blood derived MSCs for HBV-related ACLF patients.